Published in Cancer Weekly, November 5th, 2002
TransMID is based on the transferrin-mediated delivery of a modified diphtheria toxin, which is capable of selectively killing cancer cells. A completed phase II study conducted in leading neuro-oncology centers in the U.S.A. showed highly promising clinical response rates and an improvement in survival times in patients with recurrent brain...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.